Management of chronic hepatitis B in special populations: Immunosuppressed patients and chronic kidney disease

Fabrizio Fabrizi, Vivek Dixit, Piergiorgio Messa, Paul Martin

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Hepatitis B virus (HBV) infection remains an important cause of liver disease in the population with chronic kidney disease, including patients on long-term dialysis and renal transplant (RT) recipients. Diminished survival due to hepatitis B has been observed after RT. A thorough evaluation, including liver biopsy as well as assessment of serum markers of HBV replication (ie, hepatitis B e antigen and/or HBV DNA) is required before transplantation. Tolerance to interferon is poor both in dialysis patients and after renal transplant. Oral antiviral therapy now permits safe and potent antiviral treatment of HBV-related liver disease in chronic kidney disease patients with prevention of progressive liver disease. Preliminary evidence shows an improved survival of HBsAg positive renal allograft recipients on antiviral therapy. However, numerous issues concerning the treatment of hepatitis B in the population with chronic kidney disease remain unclear and further clinical trials are needed.

Original languageEnglish (US)
Pages (from-to)269-276
Number of pages8
JournalCurrent Hepatitis Reports
Volume10
Issue number4
DOIs
StatePublished - Dec 1 2011

Keywords

  • Chronic kidney disease
  • Hepatitis B Virus
  • Immunosuppressive therapy
  • Kidney transplantation
  • Special populations
  • Survival

ASJC Scopus subject areas

  • Hepatology
  • Virology

Fingerprint Dive into the research topics of 'Management of chronic hepatitis B in special populations: Immunosuppressed patients and chronic kidney disease'. Together they form a unique fingerprint.

  • Cite this